BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2130005)

  • 1. Antibacterial activity of combined cefotaxime and desacetyl-cefotaxime against aerobic and anaerobic gram-negative bacilli.
    Marone P; Navarra A; Monzillo V; Traverso A
    Drugs Exp Clin Res; 1990; 16(12):629-33. PubMed ID: 2130005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro evaluation of the activity and interactions of cefotaxime and its metabolite desacetylcefotaxime against strains of enterobacteria, staphylococci and Bacteroides fragilis isolated from hospital infections].
    Pitzus E
    G Ital Chemioter; 1989; 36(1-3):57-64. PubMed ID: 2488914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.
    Jones RN; Pfaller MA; Fuchs PC; Aldridge K; Allen SD; Gerlach EH
    Diagn Microbiol Infect Dis; 1989; 12(6):489-94. PubMed ID: 2560421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro studies on cefotaxime and desacetylcefotaxime.
    Selwyn S; Bakhtiar M
    Drugs Exp Clin Res; 1986; 12(12):953-65. PubMed ID: 3494587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.
    Limbert M; Seibert G; Schrinner E
    Infection; 1982; 10(2):97-100. PubMed ID: 6284653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
    Edmiston CE; Krepel CJ; Clausz JC; Condon RE
    Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of cefotaxime and desacetylcefotaxime against pathogenic bacteria. Assessment with the serum bactericidal test.
    Reller LB
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):55S-61S. PubMed ID: 6086219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
    Thabaut A; Meyran M; Huerre M
    Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro studies with ceftazidime against aerobic gram-negative bacilli and Bacteroides fragilis group.
    Acuna G; Johnston J; Young LS; Martin WJ
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():83-9. PubMed ID: 19810170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of isepamicin (SCH21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin and piperacillin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci.
    Jones RN; Johnson DM; Barrett MS; Erwin ME
    J Chemother; 1991 Oct; 3(5):289-94. PubMed ID: 1809808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in-vitro activity of three long-acting cephalosporins against Bacteroides fragilis, Peptostreptococcus species and Clostridium perfringens.
    Watt B; Naden MG
    Chemioterapia; 1988 Aug; 7(4):264-6. PubMed ID: 2902937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.